Article

Can Bone Material Strength Index Predict Fracture Risk?

Author(s):

A new study suggests that bone material strength index (BMSi) is weakly associated with spine and hip areal bone mineral density (aBMD) but not with prevalent fracture in women.

A Swedish study in Osteoporosis International suggests that bone material strength index (BMSi) is weakly associated with spine and hip areal bone mineral density (aBMD) but not with prevalent fracture in women.

Bone mineral density (BMD is a well-studied predictor of fracture risk and is used as the golden standard to diagnose osteoporosis and determine fracture risk today. But the relationship between BMSi and fracture is poorly understood. In previous studies, low BMSi values have been observed in patients with prior fracture than in controls, but no association between BMSi and aBMD has been found.

The current study used reference point indentation, a novel method for assessing BMSi in vivo, to measure BMSi in 211 women with a mean age of 78.3 ± 1.1 years. Areal BMD of the hip, spine, and non-dominant radius was measured using dual-energy X-ray absorptiometry (DXA). Fracture history was retrieved using questionnaires, and vertebral fractures were identified using vertebral fracture assessment (VFA) by DXA.

Fracture history was retrieved by a questionnaire, and subjects were asked to report fracture site and their age at the time of the fracture. Peripheral fractures were defined as fractures of the limbs excluding feet and hands (ie, radius, ulna, humerus, tibia, fibula, and the femur). Osteoporotic fractures were defined by skeletal site as fractures of the distal forearm, proximal humerus, vertebral fractures, hip fractures, and pelvic fractures. Only moderate and severe vertebral fractures were accounted for as prevalent fractures whereas subjects with only mild fractures were excluded from further analysis.

“It has not yet been well characterized what BMSi actually measures, in terms of bone material properties,” the authors observed. “We speculate that the cortical bone would be deteriorated, with a high age-dependent cortical porosity in our cohort of older women, which would then be expected to negatively influence BMSi in the cortical bone. Therefore, peripheral fractures, to which cortical bone probably contributes the most, were also investigated in relation to BMSi. Surprisingly, there was no tendency of any association between BMSi and these fractures, indicating that BMSi does not reflect bone fragility in our particular study population. In some clinical situations, bone material properties may play a more predominant role in decreasing bone strength, like younger individuals with fragility fractures, diabetes, or incident use of glucocorticoids.”

The study results directly contradict an earlier study that found an association between prevalent fracture and BMSi. Because of this disagreement, the study authors would like to see further research to establish if BMSi can help characterize skeletal fragility and improve fracture prediction, in particular in older populations.

Related Videos
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
© 2024 MJH Life Sciences

All rights reserved.